0.7052
Kronos Bio Inc stock is traded at $0.7052, with a volume of 2.56M.
It is down -1.29% in the last 24 hours and down -15.65% over the past month.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
See More
Previous Close:
$0.7144
Open:
$0.7112
24h Volume:
2.56M
Relative Volume:
8.00
Market Cap:
$51.88M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.3616
EPS:
-1.95
Net Cash Flow:
$-79.26M
1W Performance:
-17.13%
1M Performance:
-15.65%
6M Performance:
-28.77%
1Y Performance:
-31.53%
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
(650) 781-5200
Address
1300 S. EL CAMINO REAL, SAN MATEO
Compare KRON with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KRON
Kronos Bio Inc
|
0.7052 | 51.88M | 0 | -112.67M | -79.26M | -1.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-14-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Nov-14-24 | Downgrade | TD Cowen | Buy → Hold |
Sep-14-22 | Initiated | Berenberg | Buy |
Oct-20-21 | Resumed | Cowen | Outperform |
Jun-24-21 | Initiated | H.C. Wainwright | Buy |
Nov-03-20 | Initiated | Cowen | Outperform |
Nov-03-20 | Initiated | Goldman | Buy |
Nov-03-20 | Initiated | Jefferies | Buy |
Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
KRON Shares Experience Decline in Value - knoxdaily.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Kronos shares slump on Concentra takeover news - The Pharma Letter
Kronos Bio (KRON) to Merge with Concentra Biosciences in $0.57 P - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc.KRON - PR Newswire
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals
Now Is The Time To Build A Position In Kronos Bio Inc (NASDAQ:KRON) - Marketing Sentinel
KRON’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - investchronicle.com
Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall - marketscreener.com
Today’s watch list includes Kronos Bio Inc (NASDAQ:KRON) stock - uspostnews.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancor - Morningstar
Kronos Bio stock hits 52-week low at $0.68 amid market challenges - Investing.com India
After hunt for alternatives, Kronos Bio selects Tang Capital’s Concentra for a deal - Endpoints News
Kronos Bio (KRON) to be Acquired by Concentra Biosciences in Strategic Merger | KRON Stock News - GuruFocus
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders - The Joplin Globe
The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders - FinancialContent
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders - The Joplin Globe
Concentra To Acquire Kronos Bio - Nasdaq
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - The Manila Times
Kronos Bio agrees to Concentra Biosciences acquisition - Investing.com
Kronos Bio Enters into Agreement to Be Acquired by - GlobeNewswire
Kronos Bio (KRON) Projected to Announce Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $1.11 Million Position in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio ends lease early, pays $1.4 million settlement - Investing.com Australia
Kronos Bio ends lease early, pays $1.4 million settlement By Investing.com - Investing.com Canada
Kronos Bio Announces Lease Termination Agreement - TipRanks
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors - The Manila Times
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Kronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023) - Yahoo Finance
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Kronos Bio earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
Kronos Bio, Inc. SEC 10-K Report - TradingView
China Revives Its Carbon Credit Market: Price Swings & Future Outlook - The Globe and Mail
Navigating the U.S. Planting Season with Enhanced Risk Management - The Globe and Mail
Shootin' the Bull about cattle feeders - The Globe and Mail
KRONOS BIO Earnings Preview: Recent $KRON Insider Trading, Hedge Fund Activity, and More - Nasdaq
Kronos Bio (KRON) to Release Quarterly Earnings on Thursday - Defense World
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Kronos Bio Insider Ups Holding By 36% During Year - Yahoo Finance
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Kronos Bio, Inc. (NASDAQ:KRON) Shares Sold by Partners Capital Investment Group LLP - MarketBeat
Peapod Lane Capital LLC Purchases New Position in Kronos Bio, Inc. (NASDAQ:KRON) - MarketBeat
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5% - MarketBeat
Kronos Bio Inc Stock (KRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):